A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma

Point mutations of the fibroblast growth factor receptor (FGFR)2 receptor in intrahepatic cholangiocarcinoma (iCC) are mainly of unknown functional significance compared to FGFR2 fusions. Pemigatinib, a tyrosine kinase inhibitor, is approved for the treatment of cholangiocarcinoma with FGFR2 fusion/...

Descripción completa

Detalles Bibliográficos
Autores principales: Hempel, Louisa, Lapa, Constantin, Dierks, Alexander, Gaumann, Andreas, Scheiber, Josef, Veloso de Oliveira, Julia, Philipp, Patrick, Oyarzun Laura, Cristina, Wesarg, Stefan, Robert, Sebastian, Hempel, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520138/
https://www.ncbi.nlm.nih.gov/pubmed/36188486
http://dx.doi.org/10.1177/17588359221125096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520138/
https://www.ncbi.nlm.nih.gov/pubmed/36188486
http://dx.doi.org/10.1177/17588359221125096

Ejemplares similares